Putnam Investments LLC decreased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 25.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,738,784 shares of the medical instruments supplier’s stock after selling 583,557 shares during the quarter. Becton Dickinson and comprises approximately 1.0% of Putnam Investments LLC’s holdings, making the stock its 20th biggest holding. Putnam Investments LLC’s holdings in Becton Dickinson and were worth $438,191,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Duality Advisers LP lifted its holdings in shares of Becton Dickinson and by 12.7% during the 1st quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock valued at $4,365,000 after acquiring an additional 1,970 shares in the last quarter. Meridian Wealth Advisors LLC lifted its holdings in shares of Becton Dickinson and by 2.7% during the 1st quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock valued at $946,000 after acquiring an additional 99 shares in the last quarter. Eagle Asset Management Inc. acquired a new position in shares of Becton Dickinson and during the 2nd quarter valued at $2,062,000. GAM Holding AG lifted its holdings in shares of Becton Dickinson and by 56.4% during the 2nd quarter. GAM Holding AG now owns 48,870 shares of the medical instruments supplier’s stock valued at $12,316,000 after acquiring an additional 17,622 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its holdings in shares of Becton Dickinson and by 0.5% during the 2nd quarter. CIBC Asset Management Inc now owns 53,480 shares of the medical instruments supplier’s stock valued at $13,477,000 after acquiring an additional 247 shares in the last quarter. Institutional investors and hedge funds own 84.21% of the company’s stock.
BDX has been the topic of several recent research reports. Morgan Stanley lifted their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Wells Fargo & Co boosted their price objective on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Finally, Piper Jaffray Companies cut their price objective on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $266.55.
In other news, CEO Vincent A. Forlenza sold 11,532 shares of the business’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the sale, the chief executive officer now owns 218,671 shares of the company’s stock, valued at approximately $56,937,554.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP James C. Lim sold 9,299 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $263.53, for a total transaction of $2,450,565.47. Following the completion of the sale, the executive vice president now directly owns 33,041 shares of the company’s stock, valued at approximately $8,707,294.73. The disclosure for this sale can be found here. Insiders sold a total of 37,249 shares of company stock worth $9,616,803 in the last quarter. 0.12% of the stock is currently owned by company insiders.
BDX stock traded down $0.09 during trading on Tuesday, reaching $258.73. The stock had a trading volume of 29,146 shares, compared to its average volume of 908,221. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $70.38 billion, a P/E ratio of 23.49, a PEG ratio of 1.89 and a beta of 1.13. The firm has a fifty day moving average price of $252.79 and a 200 day moving average price of $245.53.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same quarter in the previous year, the business posted $2.91 EPS. The firm’s revenue was up 1.7% compared to the same quarter last year. Sell-side analysts predict that Becton Dickinson and Co will post 11.68 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 dividend on an annualized basis and a yield of 1.19%. Becton Dickinson and’s dividend payout ratio is currently 27.97%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Limitations to arbitrage trading
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.